Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-08
2007-05-08
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S340000, C514S341000, C514S342000, C514S343000, C514S345000, C546S269700, C546S271400, C546S272700, C546S290000, C546S304000
Reexamination Certificate
active
10683125
ABSTRACT:
This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or h) inducing apoptosis in a cancer cell.
REFERENCES:
patent: 6174905 (2001-01-01), Suzuki et al.
patent: WO 02/16310 (2002-02-01), None
Matsumoto Alvin M “Hormonal Therapy of Male Hypogonadism” Endocrinology and Metabolism Clinics of North America, 0889-8529/94, 23:857-75 (1994).
Zhou Zong-xun et al. “Specificity of Ligang-Dependent Androgen Receptor Stabilization: Receptor Domain Interactions Influence Ligand Dissociation and Receptor Stability”, Molecular Endocrinology, 9:208-18 (1995).
Sundaram Kalyan et al., “7 Alpha-Methyl-Nortestosterone(MENT): The Optimal Androgen For Male Contraception,” Ann. Med., 25:199-205 (1993).
Steinberger Emil et al., “Effect of Chronic Administration of Testosterone Enanthate on Sperm Production and Plasma Testosterone, Follicle Stimulating Hormone, and Luteinizing Hormone Levels: A Preliminary Evaluation of a Possible Male Contraceptive”, Fertility and Sterility 28:1320-28 (1977).
World Health Organization Task Force on Methods And Regulation of Male Fertility, “Contraceptive Efficacy of Testosterone-Induced Azoospermia and Oligospermia in Normal Men,” Fertility and Sterility 65:821-29 (1996).
Wu Frederick C. W. et al, “Effects of Testosterone Enanthate in Normal Men: Experience From a Multicenter Contraceptive Efficacy Study,” Fertility and Sterility 65:626-36 (1996).
Sefton Michael V., “Implantable Pumps” CRC Crit. Ref. Biomed. Eng. 14:201 (1987).
Buchwald Henry et al., “Long-Term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis” Surgery 88:507 (1980).
Saudek Christopher D. et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery” New England Journal of Medicine, 321:574 (1989).
Goodson J. Max “Dental Applications” Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984).
Langer Robert “New Method of Drug Delivery” Science 249:1527-1533 (1990).
Dalton James T.
Miller Duane D.
Cohen Mark S.
Davis Zinna N.
University of Tennessee Research Foundation
LandOfFree
Heterocyclic selective androgen receptor modulators and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic selective androgen receptor modulators and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic selective androgen receptor modulators and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3818714